Omapatrilat is primarily utilized in the field of cardiovascular medicine due to its dual inhibitory action on both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). This dual mechanism makes it effective in managing hypertension and heart failure. By inhibiting ACE, it reduces the production of angiotensin II, a potent vasoconstrictor, leading to lowered blood pressure. Simultaneously, its inhibition of NEP prevents the breakdown of natriuretic peptides, which promote vasodilation and sodium excretion, further aiding in blood pressure regulation and fluid balance. Clinical studies have explored its potential as a therapeutic agent for patients with resistant hypertension or congestive heart failure, offering a more comprehensive approach compared to single-target inhibitors. However, its development has been limited due to concerns about side effects, such as angioedema, which have restricted its widespread clinical use.